FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Joseph O'Donoghue

Research Profile

Chemicals & Drugs

Procedures

Disorders

Concepts & Ideas

Living Beings

Physiology

Devices

Radiometry

Co-author Network

Publications

TOP 3
Jazmin Schwartz; Chaitanya R Divgi; John L Humm; Steven M Larson; Joseph A O'Donoghue
Bone marrow dosimetry using 124I-PET.
Joseph A O'Donoghue; Lloyd J Old; Neeta Pandit-Taskar; Daniel A Pryma; Shutian Ruan; Peter Smith-Jones; Vivian E Strong; Jorge Carrasquillo; Chaitanya R Divgi; Yuman Fong; John L Humm; Achim A Jungbluth; Nancy E Kemeny; Steven M Larson
124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET.
Jorge A Carrasquillo; Chaitanya R Divgi; Yuman Fong; Mithat Gonen; John L Humm; Jaspreet S Jaggi; Achim A Jungbluth; Nancy E Kemeny; Joseph A O'Donoghue; Lloyd J Old; Katherine S Panageas; Neeta Pandit-Taskar; Daniel A Pryma; Gerd Ritter; Shutian Ruan; David A Scheinberg; Peter Smith-Jones; Douglas Wong; Pat Zanzonico; Steven M Larson
(124)I-huA33 antibody PET of colorectal cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Joseph O'Donoghue (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Jazmin Schwartz; Chaitanya R Divgi; John L Humm; Steven M Larson; Joseph A O'Donoghue
Bone marrow dosimetry using 124I-PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2012;53(4):615-21.
2011: Joseph A O'Donoghue; Lloyd J Old; Neeta Pandit-Taskar; Daniel A Pryma; Shutian Ruan; Peter Smith-Jones; Vivian E Strong; Jorge Carrasquillo; Chaitanya R Divgi; Yuman Fong; John L Humm; Achim A Jungbluth; Nancy E Kemeny; Steven M Larson
124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(12):1878-85.
2011: Jorge A Carrasquillo; Chaitanya R Divgi; Yuman Fong; Mithat Gonen; John L Humm; Jaspreet S Jaggi; Achim A Jungbluth; Nancy E Kemeny; Joseph A O'Donoghue; Lloyd J Old; Katherine S Panageas; Neeta Pandit-Taskar; Daniel A Pryma; Gerd Ritter; Shutian Ruan; David A Scheinberg; Peter Smith-Jones; Douglas Wong; Pat Zanzonico; Steven M Larson
(124)I-huA33 antibody PET of colorectal cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(8):1173-80.
2011: Daniel A Pryma; Joseph A O'Donoghue; John L Humm; Achim A Jungbluth; Lloyd J Old; Steven M Larson; Chaitanya R Divgi
Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(4):535-40.
2011: Christoph Oehler; Joseph A O'Donoghue; James Russell; Pat Zanzonico; Sylvie Lorenzen; C Clifton Ling; Sean Denis Carlin
18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(3):437-44.
2011: J Schwartz; Jaspreet Singh Jaggi; Joseph A O'Donoghue; Shutian Ruan; Michael R McDevitt; Steven M Larson; David A Scheinberg; John L Humm
Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody.
Physics in medicine and biology 2011;56(3):721-33.
2010: Xiao-Feng Li; Yuanyuan Ma; Xiaorong Sun; John L Humm; C Clifton Ling; Joseph A O'Donoghue
High 18F-FDG uptake in microscopic peritoneal tumors requires physiologic hypoxia.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2010;51(4):632-8.
2010: Xiao-Feng Li; Xiaorong Sun; Yuanyuan Ma; Makiko Suehiro; Mutian Zhang; James Russell; John L Humm; C Clifton Ling; Joseph A O'Donoghue
Detection of hypoxia in microscopic tumors using 131I-labeled iodo-azomycin galactopyranoside (131I-IAZGP) digital autoradiography.
European journal of nuclear medicine and molecular imaging 2010;37(2):339-48.
2009: Sean Denis Carlin; Andrei Pugachev; Xiaorong Sun; Sean Burke; Filip Claus; Joseph A O'Donoghue; C Clifton Ling; John L Humm
In vivo characterization of a reporter gene system for imaging hypoxia-induced gene expression.
Nuclear medicine and biology 2009;36(7):821-31.
2009: Makiko Suehiro; Paul Burgman; Sean Denis Carlin; Sean Burke; Guangbin Yang; Ouathek Ouerfelli; Christoph Oehler-Janne; Joseph A O'Donoghue; C Clifton Ling; John L Humm
Radiosynthesis of [(131)I]IAZGP via nucleophilic substitution and its biological evaluation as a hypoxia marker - is specific activity a factor influencing hypoxia-mapping ability of a hypoxia marker?
Nuclear medicine and biology 2009;36(5):477-87.
2009: Wenli Wang; Jens-Christoph Georgi; Sadek A Nehmeh; Manoj Narayanan; Timo Paulus; Matthieu Bal; Joseph A O'Donoghue; Pat Zanzonico; C Ross Schmidtlein; Nancy Y Lee; John L Humm
Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging.
Physics in medicine and biology 2009;54(10):3083-99.
2009: Michael J Morris; Neeta Pandit-Taskar; Jorge Carrasquillo; Chaitanya R Divgi; Susan F Slovin; W Kevin Kelly; Dana Elizabeth Rathkopf; Gretchen A Gignac; David B Solit; Lawrence H Schwartz; Ryan D Stephenson; Christina Hong; Anthony Delacruz; Tracy Curley; Glenn Heller; Xiaoyu Jia; Joseph A O'Donoghue; Steven M Larson; Howard I Scher
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(15):2436-42.
2009: HyungJoon Cho; Ellen Ackerstaff; Sean Denis Carlin; Mihaela E Lupu; Ya Wang; Asif Rizwan; Joseph A O'Donoghue; C Clifton Ling; John L Humm; Pat Zanzonico; Jason A Koutcher
Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia.
Neoplasia (New York, N.Y.) 2009;11(3):247-59, 2p following 259.
2008: Neeta Pandit-Taskar; Joseph A O'Donoghue; Michael J Morris; Eze A Wills; Lawrence H Schwartz; Mithat Gonen; Howard I Scher; Steven M Larson; Chaitanya R Divgi
Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2008;49(7):1066-74.
2008: Xiao-Feng Li; Joseph A O'Donoghue
Hypoxia in microscopic tumors.
Cancer letters 2008;264(2):172-80.
2008: Peter Smith-Jones; Neeta Pandit-Taskar; Wei Cao; Joseph A O'Donoghue; Martin D Philips; Jorge Carrasquillo; Jason Konner; Lloyd J Old; Steven M Larson
Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.
Nuclear medicine and biology 2008;35(3):343-51.
2008: Mutian Zhang; Qing Chen; Xiao-Feng Li; Joseph A O'Donoghue; Shutian Ruan; Pat Zanzonico; C Clifton Ling; John L Humm
Image deconvolution in digital autoradiography: a preliminary study.
Medical physics 2008;35(2):522-30.
2007: Xiao-Feng Li; Sean Denis Carlin; Muneyasu Urano; James Russell; C Clifton Ling; Joseph A O'Donoghue
Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy.
Cancer research 2007;67(16):7646-53.
2007: Michael J Morris; Neeta Pandit-Taskar; Chaitanya R Divgi; Samantha Bender; Joseph A O'Donoghue; Angelo Nacca; Peter Smith-Jones; Lawrence H Schwartz; Susan F Slovin; Ronald Finn; Steven M Larson; Howard I Scher
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(9):2707-13.
2006: Bixiu Wen; Muneyasu Urano; Joseph A O'Donoghue; C Clifton Ling
Measurements of partial oxygen pressure pO2 using the OxyLite system in R3327-AT tumors under isoflurane anesthesia.
Radiation research 2006;166(3):512-8.
2006: Xiao-Feng Li; Pat Zanzonico; C Clifton Ling; Joseph A O'Donoghue
Visualization of experimental lung and bone metastases in live nude mice by X-ray micro-computed tomography.
Technology in cancer research & treatment 2006;5(2):147-55.
2005: Michael J Morris; Chaitanya R Divgi; Neeta Pandit-Taskar; Maria Batraki; Nyasha Warren; Angelo Nacca; Peter Smith-Jones; Lawrence H Schwartz; W Kevin Kelly; Susan F Slovin; David B Solit; Jennifer Halpern; Anthony Delacruz; Tracy Curley; Ronald Finn; Joseph A O'Donoghue; Philip O Livingston; Steven M Larson; Howard I Scher
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7454-61.
2005: Paul Burgman; Joseph A O'Donoghue; Jason S Lewis; Michael J Welch; John L Humm; C Clifton Ling
Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM.
Nuclear medicine and biology 2005;32(6):623-30.
2005: Joseph A O'Donoghue; Pat Zanzonico; Andrei Pugachev; Bixiu Wen; Peter Smith-Jones; Shangde Cai; Eva Burnazi; Ronald D Finn; Paul Burgman; Shutian Ruan; Jason S Lewis; Michael J Welch; C Clifton Ling; John L Humm
Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
International journal of radiation oncology, biology, physics 2005;61(5):1493-502.
2004: Bixiu Wen; Paul Burgman; Pat Zanzonico; Joseph A O'Donoghue; Shangde Cai; Ronald Finn; Inna Serganova; Ronald Blasberg; Juri G Gelovani; Gloria C Li; C Clifton Ling
A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia.
European journal of nuclear medicine and molecular imaging 2004;31(11):1530-8.
2004: Chaitanya R Divgi; Joseph A O'Donoghue; Sydney Welt; Jayne O'Neel; Ronald Finn; Robert J Motzer; Achim Jungbluth; Eric Hoffman; Gerd Ritter; Steven M Larson; Lloyd J Old
Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2004;45(8):1412-21.
2004: Joseph A O'Donoghue
Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy.
Cancer biotherapy & radiopharmaceuticals 2004;19(3):378-87.
2004: Pat Zanzonico; Joseph A O'Donoghue; J Donald Chapman; Richard Schneider; Shangde Cai; Steven M Larson; Bixiu Wen; Yuchun Chen; Ronald Finn; Shutian Ruan; Leo Gerweck; John L Humm; C Clifton Ling
Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning.
European journal of nuclear medicine and molecular imaging 2004;31(1):117-28.
2003: John L Humm; Douglas Ballon; Y C Hu; Shutian Ruan; Chen Chui; P Karina Tulipano; Alev K Erdi; Jason A Koutcher; Kristen L Zakian; Muneyasu Urano; Pat Zanzonico; C Mattis; Jonathan P Dyke; Yuchun Chen; P Harrington; Joseph A O'Donoghue; C Clifton Ling
A stereotactic method for the three-dimensional registration of multi-modality biologic images in animals: NMR, PET, histology, and autoradiography.
Medical physics 2003;30(9):2303-14.
2002: Joseph A O'Donoghue; Nanaefua Baidoo; Devie Deland; Sydney Welt; Chaitanya R Divgi; George Sgouros
Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy.
Cancer biotherapy & radiopharmaceuticals 2002;17(4):435-43.
2002: James Russell; Joseph A O'Donoghue; Ronald Finn; Jacek Koziorowski; Shutian Ruan; John L Humm; C Clifton Ling
Iodination of annexin V for imaging apoptosis.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2002;43(5):671-7.
2002: Gerald L DeNardo; Jeffery Schlom; Donald J Buchsbaum; Ruby F Meredith; Joseph A O'Donoghue; George Sgouros; John L Humm; Sally J DeNardo
Rationales, evidence, and design considerations for fractionated radioimmunotherapy.
Cancer 2002;94(4 Suppl):1332-48.
2001: EC Barendswaard; John L Humm; Joseph A O'Donoghue; George Sgouros; Ronald D Finn; Andrew M Scott; Steven M Larson; Sydney Welt
Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2001;42(8):1251-6.
2000: Shutian Ruan; Joseph A O'Donoghue; Steven M Larson; Ronald D Finn; Achim Jungbluth; Sydney Welt; John L Humm
Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2000;41(11):1905-12.
2000: Joseph A O'Donoghue; George Sgouros; Chaitanya R Divgi; John L Humm
Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2000;41(3):538-47.
1999: EC Barendswaard; Joseph A O'Donoghue; Steven M Larson; Jorg Tschmelitsch; Sydney Welt; Ronald D Finn; John L Humm
131I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(10):1764-8.
1999: Joseph A O'Donoghue
Implications of nonuniform tumor doses for radioimmunotherapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(8):1337-41.
1998: Chaitanya R Divgi; Neil H Bander; Andrew M Scott; Joseph A O'Donoghue; George Sgouros; Sydney Welt; Ronald D Finn; F Morrissey; P Capitelli; J M Williams; Devie Deland; A Nakhre; Egbert Oosterwijk; S Gulec; MC Graham; Steven M Larson; Lloyd J Old
Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(11):2729-39.
1998: George Sgouros; Joseph A O'Donoghue; Steven M Larson; Homer A Macapinlac; J J Larson; Nancy Kemeny
Mathematical model of 5-[125I]iodo-2'-deoxyuridine treatment: continuous infusion regimens for hepatic metastases.
International journal of radiation oncology, biology, physics 1998;41(5):1177-83.
1998: A Loh; George Sgouros; Joseph A O'Donoghue; Devie Deland; Dev R Puri; P Capitelli; John L Humm; Steven M Larson; Lloyd J Old; Chaitanya R Divgi
Pharmacokinetic model of iodine-131-G250 antibody in renal cell carcinoma patients.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1998;39(3):484-9.
1998: L Martin; B Baker; D Fairall; K Florell; A Foster; K Gilbert; Joseph A O'Donoghue
A code of ethics for the medical dosimetrist--the American Association of Medical Dosimetrists experience.
Medical dosimetry : official journal of the American Association of Medical Dosimetrists 1998;23(4):346-7.
1998: L Martin; B Baker; D Fairall; K Florell; A Foster; K Gilbert; Joseph A O'Donoghue
A code of ethics for the medical dosimetrist--the American Association of Medical Dosimetrists experience.
Medical dosimetry : official journal of the American Association of Medical Dosimetrists 1998;23(3):257-8.
1998: L Martin; B Baker; D Fairall; K Florell; A Foster; K Gilbert; Joseph A O'Donoghue
A code of ethics for the medical dosimetrist--the American Association of Medical Dosimetrists experience.
Medical dosimetry : official journal of the American Association of Medical Dosimetrists 1998;23(2):131-2.
1998: L Martin; B Baker; D Fairall; K Florell; A Foster; K Gilbert; Joseph A O'Donoghue
A code of ethics for the medical dosimetrist--the American Association of Medical Dosimetrists experience.
Medical dosimetry : official journal of the American Association of Medical Dosimetrists 1998;23(1):85-6.
1997: Joseph A O'Donoghue
The response of tumours with Gompertzian growth characteristics to fractionated radiotherapy.
International journal of radiation biology 1997;72(3):325-39.
1997: Roger G Dale; Ian P Coles; C Deehan; Joseph A O'Donoghue
Calculation of integrated biological response in brachytherapy.
International journal of radiation oncology, biology, physics 1997;38(3):633-42.
1997: L Martin; B Baker; D Fairall; K Florell; A Foster; K Gilbert; Joseph A O'Donoghue
A code of ethics for the medical dosimetrist--the American Association of Medical Dosimetrists experience.
Medical dosimetry : official journal of the American Association of Medical Dosimetrists 1997;22(4):339-40.
1997: L Martin; B Baker; D Fairall; K Florell; A Foster; K Gilbert; Joseph A O'Donoghue
A code of ethics for the medical dosimetrist--the American Association of Medical Dosimetrists experience.
Medical dosimetry : official journal of the American Association of Medical Dosimetrists 1997;22(3):265-6.
1996: Joseph A O'Donoghue; T E Wheldon
Targeted radiotherapy using Auger electron emitters.
Physics in medicine and biology 1996;41(10):1973-92.
1996: Joseph A O'Donoghue
Strategies for selective targeting of Auger electron emitters to tumor cells.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1996;37(4 Suppl):3S-6S.
1996: Joseph A O'Donoghue
Optimal therapeutic strategies for radioimmunotherapy.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1996;141():77-99.
1995: Joseph A O'Donoghue; M Bardiès; TE Wheldon
Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1995;36(10):1902-9.
1995: amin amin; TE Wheldon; Joseph A O'Donoghue; Mark Gaze; A Barrett
Optimum combination of targeted 131I and total body irradiation for treatment of disseminated cancer.
International journal of radiation oncology, biology, physics 1995;32(3):713-21.
1995: Mark Gaze; TE Wheldon; Joseph A O'Donoghue; T E Hilditch; S G McNee; E Simpson; A Barrett
Multi-modality megatherapy with [131I]meta-iodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: feasibility study of a new strategy for advanced neuroblastoma.
European journal of cancer (Oxford, England : 1990) 1995;31A(2):252-6.
1995: Robert J Mairs; J Russell; S Cunningham; Joseph A O'Donoghue; Mark Gaze; J Owens; G Vaidyanathan; M R Zalutsky
Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
European journal of cancer (Oxford, England : 1990) 1995;31A(4):576-81.
1994: Joseph A O'Donoghue
The impact of tumor cell proliferation in radioimmunotherapy.
Cancer 1994;73(3 Suppl):974-80.
1994: A Livingstone; Robert J Mairs; J Russell; Joseph A O'Donoghue; Mark Gaze; TE Wheldon
N-myc gene copy number in neuroblastoma cell lines and resistance to experimental treatment.
European journal of cancer (Oxford, England : 1990) 1994;30A(3):382-9.
1993: amin amin; TE Wheldon; Joseph A O'Donoghue; A Barrett
Radiobiological modeling of combined targeted 131I therapy and total body irradiation for treatment of disseminated tumors of differing radiosensitivity.
International journal of radiation oncology, biology, physics 1993;27(2):323-30.
1993: P Morgan-Capner; G A Holbrook; Joseph A O'Donoghue
HIV and insurance.
BMJ (Clinical research ed.) 1993;307(6907):805.
1993: Joseph A O'Donoghue; Mark Gaze; J T Kemshead
Third L. H. Gray Workshop, Kelvin Conference Centre, University of Glasgow, Scotland, 24-25 March 1992: The radiobiology of targeted radiotherapy.
International journal of radiation biology 1993;63(2):247-50.
1993: TE Wheldon; Joseph A O'Donoghue; A Barrett
Kinetic considerations in the choice of treatment schedules for neuraxis radiotherapy.
The British journal of radiology 1993;66(781):61-6.
1992: amin amin; TE Wheldon; Joseph A O'Donoghue; A Barrett
Optimum combination of targeted 131I therapy and total-body irradiation for treatment of disseminated tumors of differing radiosensitivity.
Cell biophysics 1992;21(1-3):139-52.
1991: Joseph A O'Donoghue
Optimal scheduling of biologically targeted radiotherapy and total body irradiation with bone marrow rescue for the treatment of systemic malignant disease.
International journal of radiation oncology, biology, physics 1991;21(6):1587-94.
1991: TE Wheldon; Joseph A O'Donoghue; A Barrett; A S Michalowski
The curability of tumours of differing size by targeted radiotherapy using 131I or 90Y.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1991;21(2):91-9.
1991: Joseph A O'Donoghue; TE Wheldon; John Babich; J S Moyes; A Barrett; S T Meller
Implications of the uptake of 131I-radiolabelled meta-iodobenzylguanidine (mIBG) for the targeted radiotherapy of neuroblastoma.
The British journal of radiology 1991;64(761):428-34.
1991: Joseph A O'Donoghue; TE Wheldon; John Babich; J S Moyes; A Barrett; S T Meller
Therapeutic implications of the uptake of radiolabelled mIBG for the treatment of neuroblastoma.
Progress in clinical and biological research 1991;366():455-61.
1990: Joseph A O'Donoghue
Isoeffect relationships for fractionated biologically targeted radiotherapy.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1990;19(3):257-65.
1990: TE Wheldon; Joseph A O'Donoghue
The radiobiology of targeted radiotherapy.
International journal of radiation biology 1990;58(1):1-21.
1989: Joseph A O'Donoghue; TE Wheldon
Dose-rate effects in biologically targeted radiotherapy.
International journal of radiation biology 1989;56(5):745-9.
1989: Joseph A O'Donoghue
Comparison of the predictions of the LQ and CRE models for normal tissue damage due to biologically targeted radiotherapy with exponentially decaying dose rates.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1989;15(4):359-62.
1988: C Deehan; Joseph A O'Donoghue
Biological equivalence between fractionated radiotherapy treatments using the linear-quadratic model.
The British journal of radiology 1988;61(732):1187-8.
1988: Joseph A O'Donoghue; TE Wheldon
Predicted allowable doses to normal organs for biologically targeted radiotherapy.
The British journal of radiology 1988;61(723):264-6.
1988: TE Wheldon; Joseph A O'Donoghue; T E Hilditch; A Barrett
Strategies for systemic radiotherapy of micrometastases using antibody-targeted 131I.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1988;11(2):133-42.
1987: TE Wheldon; Joseph A O'Donoghue; A Gregor
Radiobiological rationale for hyperfractionation in the radiotherapy of neuroblastoma.
International journal of radiation oncology, biology, physics 1987;13(9):1430-1.
1987: TE Wheldon; I Berry; Joseph A O'Donoghue; A Gregor; I M Hann; A Livingstone; J Russell; L Wilson
The effect on human neuroblastoma spheroids of fractionated radiation regimes calculated to be equivalent for damage to late responding normal tissues.
European journal of cancer & clinical oncology 1987;23(6):855-60.
1987: Joseph A O'Donoghue; TE Wheldon; A Gregor
The implications of in-vitro radiation-survival curves for the optimal scheduling of total-body irradiation with bone marrow rescue in the treatment of leukaemia.
The British journal of radiology 1987;60(711):279-83.
1986: Joseph A O'Donoghue
Fractionated versus low dose-rate total body irradiation. Radiobiological considerations in the selection of regimes.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1986;7(3):241-7.
1986: TE Wheldon; Joseph A O'Donoghue; A Gregor; A Livingstone; L Wilson
Radiobiological considerations in the treatment of neuroblastoma by total body irradiation.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 1986;6(4):317-26.
1986: Joseph A O'Donoghue; TE Wheldon
A radiobiological equivalence condition for radiotherapy regimes incorporating protective shielding of vulnerable normal organs.
The British journal of radiology 1986;59(703):709-11.
1986: TE Wheldon; L Wilson; A Livingstone; J Russell; Joseph A O'Donoghue; A Gregor
Radiation studies on multicellular tumour spheroids derived from human neuroblastoma: absence of sparing effect of dose fractionation.
European journal of cancer & clinical oncology 1986;22(5):563-6.
1986: Joseph A O'Donoghue
Agreement of quadratic and CRE models in predicting the late effects of continuous low dose-rate radiotherapy.
The British journal of radiology 1986;59(698):193-5.
1985: TE Wheldon; Joseph A O'Donoghue; A Gregor
Optimal scheduling of total body irradiation in the treatment of Ewing's sarcoma.
International journal of radiation oncology, biology, physics 1985;11(8):1569-70.
1985: TE Wheldon; A Livingstone; L Wilson; Joseph A O'Donoghue; A Gregor
The radiosensitivity of human neuroblastoma cells estimated from regrowth curves of multicellular tumour spheroids.
The British journal of radiology 1985;58(691):661-4.